Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Hepatitis C transmission and prevention
The New Deal: Gay Men, Sex, and Hep C

A new website has been launched, in order to provide gay men with information about sexual transmission of hepatitis C and how to prevent it; testing for and treatment of hepatitis C; and information about HIV and hepatitis C co-infection.

Published
21 hours ago
From
AFAO
Hepatitis B
High maternal viral load key to vertical transmission of hepatitis B

High maternal viral load is the most important factor causing maternally transmitted hepatitis B virus (HBV) infection and is significantly correlated with e antigen (HBeAg) positivity, according to a prospective study from Taiwan.

Published
19 March 2013
From
Medscape (requires registration)
Hepatitis C treatment
Roche’s Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older

Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) plus ribavirin for the treatment of chronic hepatitis C virus (HCV). The new label includes children and adolescents five years of age and older, who have not received treatment and who have tested positive for the virus.

Published
19 March 2013
From
Roche press release
Hepatitis C
Conference Highlights: EASL Monothematic Conference: HIV and the Liver

This was the first conference of its kind bringing together hepatologists and infectious disease specialists to address one of the critical issues in the management of HIV-infected patients: the rising mortality from liver disease. The Conference Highlights report features the key topics discussed and presented during the EASL Monothematic Conference. Email to a friend // // EASL would like to thank everyone who attended the EASL Monothematic Conference HIV and the Liver in London, UK, at the beginning of December 2012 and also thanks the European AIDS Clinical Society (EACS) for co-sponsoring the [...]

Published
14 March 2013
From
European Association for the Study of the Liver (EASL)
New and experimental hepatitis C treatment
Presidio Pharmaceuticals Announces Collaboration with Boehringer Ingelheim

The Parties to Initiate a Phase IIa Trial of an All-Oral Combination of Presidio’s HCV NS5A inhibitor (PPI-668) with Faldaprevir (BI201335) and BI207127 for the Treatment of Patients with Hepatitis C.

Published
13 March 2013
From
Presidio press release
Hepatitis C symptoms and diagnosis
Expanding High Risk Population Drives European Hepatitis B and C Diagnostics Market

New analysis from Frost & Sullivan, Analysis of the European Hepatitis B and C Diagnostics Market, estimates revenues of the hepatitis B diagnostics to grow from $165.9 million in 2012 to $260.2 million in 2019 and hepatitis C diagnostics market to grow from $3,140.8 million in 2012 to $4,940.9 million in 2019, respectively.

Published
13 March 2013
From
PR Newswire (press release)
Medical procedures and other blood-borne exposure
NY aims to prevent unsafe injections

The Safe Injection Practices Coalition, a group of healthcare-related organizations including the CDC indicated since 2001, more than 150,000 patients in the U.S. were told they may have been exposed to hepatitis B, hepatitis C, or human immunodeficiency virus because providers followed unsafe injection procedures.

Published
12 March 2013
From
UPI.com
Hepatitis C treatment
Telaprevir shows promise in black patients with genotype 1 HCV

Preliminary data presented here at the 2013 Conference on Retroviruses and Opportunistic Infections show that combination telaprevir treatment may be effective in black null responder patients with chronic genotype 1 hepatitis C.

Published
12 March 2013
From
Healio
Hepatitis C transmission and prevention
England: lack of planning for hepatitis C services risks future chaos and huge healthcare costs

New report finds that local authorities and NHS organisations need to prioritise hepatitis C now or risk missing a rare opportunity.

Published
11 March 2013
From
Hepatitis C Trust press release
Pharmaceutical industry
Pfizer stops developing hepatitis C drug

Pfizer Inc. has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease.

Published
10 March 2013
From
EATG
← First12345...48Next →

Filter by country